Skip to main content
Top

Ophthalmology and Therapy

2012 - 2025
Volumes
56
Issues
Chevron right icon
Issue 7/2025
Latest issue

Ophthalmology and Therapy OnlineFirst articles

About this journal

Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad, covering the use of ophthalmological therapies, devices, and surgical techniques. The key features of the journal are:
Rapid publication: The journal aims for a 2-week peer review, 3-4 weeks from acceptance to online.
Open access: All articles published open access (CC-BY-NC).
Inclusivity: All scientifically sound research considered be it positive, confirmatory or negative data. Research is considered from pre-clinical, clinical phase, real-world and health economics outcomes studies. Submissions are welcomed whether they relate to an international or a country-specific audience.
Personal service: The journal’s team will re-format articles and upload submissions on behalf of authors, if necessary.
Digital Features and Plain Language Summaries: These peer-reviewed features are welcomed to help enhance the educational value of a manuscript (for more information see “Author Information – Guidelines for digital features and plain language summaries” under “Submission guidelines”).
Publication fees: Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.
Contact: For more information about the journal, including pre-submission enquiries, please contact Christopher Vautrinot at christopher.vautrinot@springer.com.

Metadata
Title
Ophthalmology and Therapy
Coverage
Volume 1/2012 - Volume 14/2025
Publisher
Springer Healthcare
Electronic ISSN
2193-6528
Print ISSN
2193-8245
Journal ID
40123
DOI
https://doi.org/10.1007/40123.2193-6528

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more